Nabla Bio is a biotechnology company based in Cambridge, Massachusetts. It specializes in using artificial intelligence and advanced wet-lab techniques to design next-generation antibodies and multispecific biologics. Its proprietary platform, the Joint Atomic Model (JAM), enables precise de novo protein design, targeting diseases that traditional methods struggle to treat. Founded as a Harvard spinout, Nabla Bio partners with major pharmaceutical companies to accelerate drug discovery. By merging machine learning with experimental validation, the company aims to revolutionize how biologic medicines are created, reducing development time while expanding the possibilities of therapeutic innovation.